ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science2025
RD-LIVES: A Living Evidence Synthesis System for Rare Disease Treatment Efficacy and Safety.
Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although rare diseases (RD) are gaining priority in healthcare worldwide, developing research policies for studying them in public settings remains challenging due to the limited evidence available. Evidence generation is crucial for rare diseases, requiring systematic assessment of study quality across multiple sources. Given the scarcity of patients, literature and clinical trial data for orphan drugs, we developed RD-LIVES-a tool designed to automatically accelerate evidence collection from literature and clinical trials for systematic reviews and meta-analyses. This tool enhances our understanding of treatment outcomes, determines appropriate follow-up durations, and informs the required treatment impact size for new drugs. Using Idiopathic Pulmonary Fibrosis (IPF) as an example, we demonstrate how RD-LIVES automates evidence collection and element extraction. The results indicate that RD-LIVES plays a vital role in designing costly prospective trials and has the potential to increase the likelihood of successful trial outcomes.
Indexed as
Identifiers
40502246PMC12150729What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.